Evidence map›Paper›PMID 36835071›Full record

ArticleInternational journal of molecular sciences2023

Takato Hara, Tomoko Konishi, Shuji Yasuike, Yasuyuki Fujiwara, Chika Yamamoto, Toshiyuki Kaji

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Takato HaraFaculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
Tomoko KonishiFaculty of Pharmaceutical Sciences, Hokuriku University, Ho-3 Kanagawa-machi, Kanazawa, Ishikawa 920-1181, Japan.
Shuji YasuikeSchool of Pharmaceutical Sciences, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya, Aichi 464-8650, Japan.ORCID 0000-0001-9232-5205
Yasuyuki FujiwaraSchool of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432 Horinouchi, Hachioji, Tokyo 192-0392, Japan.ORCID 0000-0003-0028-0658
Chika YamamotoFaculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
Toshiyuki KajiFaculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chba 278-8510, Japan.ORCID 0000-0002-7393-2656
Toho University · JPAichi Gakuin University · JPHokuriku University · JPTokyo University of Pharmacy and Life Sciences · JPTokyo University of Science · JP

Funding

Japan Society for the Promotion of Science 18K06638Japan Society for the Promotion of Science 19K07005Japan Society for the Promotion of Science 19K07089Japan Society for the Promotion of Science 19K19418Japan Society for the Promotion of Science 22K17355
6 · The paper itself

Abstract

Vascular endothelial cells synthesize and secrete perlecan, a large heparan sulfate proteoglycan that increases the anticoagulant activity of vascular endothelium by inducing antithrombin III and intensifying fibroblast growth factor (FGF)-2 activity to promote migration and proliferation in the repair process of damaged endothelium during the progression of atherosclerosis. However, the exact regulatory mechanisms of endothelial perlecan expression remain unclear. Since organic-inorganic hybrid molecules are being developed rapidly as tools to analyze biological systems, we searched for a molecular probe to analyze these mechanisms using a library of organoantimony compounds and found that the

Indexed as

AntimonyEndothelial CellsHeparan Sulfate ProteoglycansOrganometallic CompoundsAnimalsAtherosclerosisCattleCells, CulturedExtracellular Matrix ProteinsHeparan SulfateAntimonyExtracellular Matrix ProteinsHeparan SulfateHeparan Sulfate ProteoglycansOrganometallic CompoundsperlecanSb-phenyl-N-methyl-5,6,7,12-tetrahydrodibenz(c,f)(1,5)azastibocinecore proteinorganoantimonyperlecanproteoglycanvascular endothelial cells

Identifiers

PMID36835071
PMCPMC9959368
OpenAlexW4320493096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.